Valneva SE, a small French biotech, is offering a vaccine that is more effective against variants of the coronavirus, according to Bloomberg. A participant from phase three trials could be given the dose this year, paving the way for shots approval in the fall.
Valneva’s shot is the only one in clinical trials using tried-and-true vaccine technology in Europe for an inactivated target virus.
The vaccine shot is expected to be a winter booster especially for older adults.
The vaccine is being tested together with AstraZeneca Plc and the University of Oxford shots and must demonstrate equal or better effectiveness.
Valneva has established a deal with the U.K to provide as much as 190 million doses.
Another supply deal is being considered with the European Commission as the company focuses on bilateral agreements with individual countries in the EU.
Valneva has recruited more staff and will increase output from three million doses to about 100 million next year after successful shots.Valneva stock is currently gaining. VLA: EPA is up 4.30%.
